bioAffinity Technologies, Inc. (NASDAQ:BIAF – Get Free Report) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 62,700 shares, a growth of 148.8% from the February 29th total of 25,200 shares. Based on an average daily trading volume, of 162,400 shares, the days-to-cover ratio is presently 0.4 days. Currently, 1.8% of the company’s stock are short sold.
bioAffinity Technologies Price Performance
bioAffinity Technologies stock traded down $0.08 during trading on Thursday, reaching $2.00. The company had a trading volume of 59,286 shares, compared to its average volume of 173,274. bioAffinity Technologies has a 12-month low of $0.95 and a 12-month high of $3.62. The stock’s 50 day moving average price is $1.77 and its two-hundred day moving average price is $1.55. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.07 and a quick ratio of 3.06.
Institutional Investors Weigh In On bioAffinity Technologies
A number of institutional investors have recently bought and sold shares of BIAF. Jane Street Group LLC purchased a new stake in bioAffinity Technologies during the third quarter worth approximately $32,000. State Street Corp purchased a new stake in bioAffinity Technologies during the first quarter worth approximately $33,000. Citadel Advisors LLC purchased a new stake in bioAffinity Technologies during the third quarter worth approximately $60,000. Finally, Two Sigma Investments LP purchased a new stake in bioAffinity Technologies during the first quarter worth approximately $50,000. 1.64% of the stock is currently owned by hedge funds and other institutional investors.
About bioAffinity Technologies
bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.
Featured Articles
- Five stocks we like better than bioAffinity Technologies
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Conference Calls and Individual Investors
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- What is a Stock Market Index and How Do You Use Them?
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
